Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

Parkinsonism and Related Disorders

Volumn 21, Issue 10, 2015, Pages 1133-1144

  Odin, P ^a,b   Ray Chaudhuri, K ^c   Slevin, J T ^d   Volkmann, J ^e   Dietrichs, E ^f   Martinez Martin, P ^g   Krauss, J K ^h   Henriksen, T ⁱ   Katzenschlager, R ^j   Antonini, A ^k   Rascol, O ^l   Poewe, W ^m   Brücke, Thomas ⁿ   Pirker, Walter ⁿ   Ransmayr, Gerhard ⁿ   Schwingenschuh, Petra ⁿ   Tomantschger, Volker ⁿ   Volc, Dieter ⁿ   Jespersen, Holger ⁿ   Kamal, Akram ⁿ   Karlsborg, Merete ⁿ   Oppel, Lorenz ⁿ   Pedersen, Stephen ⁿ   Avikainen, Sari ⁿ   Kaasinen, Valtteri ⁿ   Pekkonen, Eero ⁿ   Ruottinen, Hanna ⁿ   Azulay, Jean Philippe ⁿ   Corvol, Jean Christophe ⁿ   Courbon, Christine Brefel ⁿ   Defebvre, Luc ⁿ   Durif, Franck ⁿ   Houeto, Jean Luc ⁿ   Krack, Paul ⁿ   Tison, François ⁿ   Andrich, Jürgen ⁿ   Ehret, Reinhard ⁿ   Klostermann, Fabian ⁿ   Krüger, Rejko ⁿ   Lingor, Paul ⁿ   Liszka, Robert ⁿ   Schwarz, Johannes ⁿ   Timmermann, Lars ⁿ   Warnecke, Tobias ⁿ   Bostantjopoulou, Sevasti ⁿ   Konitsiotis, Spyridon ⁿ   Papageorgiou, Sokratis ⁿ   Stathishens, Pantelis ⁿ   Stefanis, Leonidas ⁿ   Zikos, Panagiotis ⁿ   Browne, Patrick ⁿ   Healy, Daniel ⁿ   Lynch, Timothy ⁿ   O'Riordan, Sean ⁿ   O'Sullivan, Sean ⁿ   Walsh, Richard ⁿ   Abbruzzese, Giovanni ⁿ   Lopiano, Leonardo ⁿ   Modugno, Nicola ⁿ   Tamma, Filippo ⁿ   Holmberg, Björn ⁿ   Linder, Jan ⁿ   Nyholm, Dag ⁿ   Pålhagen, Sven ⁿ   Matías Arbelo, Jos ⁿ   Bana, Rosa Yanez ⁿ   Castrillo, Juan Carlos Martinez ⁿ   Castro, Alfonso ⁿ   e Garcia Ruiz Espiga, Pedro Jos ⁿ   Kulisevsky, Jaime ⁿ   Lezcano, Elena ⁿ   Luquin, Rosario ⁿ   Mir, Pablo ⁿ   Puente, Victor ⁿ   Valldeoriola, Francesc ⁿ   Burn, David ⁿ   Clarke, Carl ⁿ   Foltynie, Thomas ⁿ   Grosset, Donald ⁿ   Hindle, John ⁿ   Leake, Alison ⁿ   Lees, Andrew ⁿ   Morris, Huw ⁿ   Stewart, David ⁿ   Walker, Richard ⁿ   Worth, Paul ⁿ   more..

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Klinikum Bremerhaven Reinkenheide   (Germany)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ BISPEBJERG HOSPITAL   (Denmark)

^j DANUBE HOSPITAL   (Austria)

^k IRCCS SAN CAMILLO HOSPITAL   (Italy)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁿ NONE   (United Kingdom)

more..

Author keywords

Device aided therapies; Dyskinesias; Motor fluctuations; Non motor symptoms; Parkinson's disease

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA;

BALANCE DISORDER; BALANCE IMPAIRMENT; BRAIN DEPTH STIMULATION; CAREGIVER; CLINICAL DECISION MAKING; COGNITIVE DEFECT; CONSULTATION; DEVICE AIDED THERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HUMAN; INFUSION PUMP; INTRAJEJUNAL DRUG ADMINISTRATION; MEDICAL INFORMATION; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); NON INVASIVE PROCEDURE; PARKINSON DISEASE; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; CONSENSUS; ORTHOPEDIC EQUIPMENT; QUESTIONNAIRE;

CONSENSUS; HUMANS; ORTHOPEDIC EQUIPMENT; PARKINSON DISEASE; SURVEYS AND QUESTIONNAIRES;

EID: 84942191840     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.07.020     Document Type: Review

References (72)

1. Lokk J. Lack of information and access to advanced treatment for Parkinson's disease patients. J. Multidiscip. Healthc. 2011, 4:433-439.
2. Worth P.F. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Pract. Neurol. 2013, 13:140-152.
3. Katzenschlager R. Apomorphine in the treatment of Parkinson's disease. Eur. Neurol. Rev. 2009, 4:28-30.
4. Olanow C.W., Kieburtz K., Odin P., Espay A.J., Standaert D.G., Fernandez H.H., et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014, 13:141-149.
5. AbbVie Duodopa Intestinal Gel: Summary of Product Characteristics 2013, https://www.medicines.org.uk/emc/medicine/20786.
6. Nyholm D., Odin P. Continuous intra-intestinal infusion of levodopa-carbidopa in advanced Parkinson's disease. Eur. Neurol. Rev. 2007, 1:45-48.
7. Odin P., Antonini A., Wolters E., Chaudhuri K.R. Selecting patients for continuous dopaminergic stimulation therapy. Eur. Neurol. Rev. 2011, 6(Suppl. 1):21-26.
8. Uc E.Y., Tippin J., Chou K.L., Erickson B.A., Doerschug K.C., Fletcher D.M.J. Non-motor symptoms in Parkinson's disease. U. S. Neurol. 2011, 7:113-119.
9. Chaudhuri K.R., Healy D.G., Schapira A.H. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
10. Witjas T., Kaphan E., Azulay J.P., Blin O., Ceccaldi M., Pouget J., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002, 59:408-413.
11. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8:464-474.
12. Zis P., Rizos A., Martinez-Martin P., Pal S., Silverdale M., Sharma J.C., et al. Non-motor symptoms profile and burden in drug naive versus long-term Parkinson's disease patients. J. Park. Dis. 2014, 4:541-547.
13. Storch A., Schneider C.B., Wolz M., Stürwald Y., Nebe A., Odin P., et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013, 80:800-809.
14. Ferreira J.J., Katzenschlager R., Bloem B.R., Bonuccelli U., Burn D., Deuschl G., et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur. J. Neurol. 2013, 20:5-15.
15. National Collaborating Centre for Chronic Conditions Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care 2006.
16. Kempster P.A., O'Sullivan S.S., Holton J.L., Revesz T., Lees A.J. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010, 133:1755-1762.
17. Volkmann J., Albanese A., Antonini A., Chaudhuri K.R., Clarke C.E., de Bie R.M., et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J. Neurol. 2013, 260:2701-2714.
18. Volkmann J., Daniels C., Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat. Rev. Neurol. 2010, 6:487-498.
19. Okun M.S., Fernandez H.H., Wu S.S., Kirsch-Darrow L., Bowers D., Bova F., et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann. Neurol. 2009, 65:586-595.
20. Follett K.A., Weaver F.M., Stern M., Hur K., Harris C.L., Luo P., et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2010, 362:2077-2091.
21. Odekerken V.J., van Laar T., Staal M.J., Mosch A., Hoffmann C.F., Nijssen P.C., et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013, 12:37-44.
22. Alegret M., Valldeoriola F., Martí M., Pilleri M., Junqué C., Rumià J., et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov. Disord. 2004, 19:1463-1469.
23. García Ruiz P.J., Sesar Ignacio A., Ares Pensado B., Castro García A., Alonso Frech F., Alvarez López M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov. Disord. 2008, 23:1130-1136.
24. Martinez-Martin P., Reddy P., Katzenschlager R., Antonini A., Todorova A., Odin P., et al. EuroInf: multicenter observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov. Disord. 2015, 30:510-516.
25. St George R.J., Nutt J.G., Burchiel K.J., Horak F.B. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010, 75:1292-1299.
26. Devos D., French D.S.G. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov. Disord. 2009, 24:993-1000.
27. Russmann H., Ghika J., Villemure J.G., Robert B., Bogousslavsky J., Burkhard P.R., et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004, 63:1952-1954.
28. Deuschl G., Agid Y. Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol. 2013, 12:1025-1034.
29. Antonini A., Isaias I.U., Rodolfi G., Landi A., Natuzzi F., Siri C., et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 2011, 258:579-585.
30. Chaudhuri K.R., Critchley P., Abbott R.J., Pye I.F., Millac P.A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988, 2:1260.
31. Colzi A., Turner K., Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:573-576.
32. Hughes A.J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A.J., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov. Disord. 1993, 8:165-170.
33. Kanovský P., Kubová D., Bares M., Hortová H., Streitová H., Rektor I., et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov. Disord. 2002, 17:188-191.
34. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 2005, 20:151-157.
35. Manson A.J., Turner K., Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov. Disord. 2002, 17:1235-1241.
36. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry 1998, 65:709-716.
37. Poewe W., Kleedorfer B., Wagner M., Bösch S., Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv. Neurol. 1993, 60:656-659.
38. Stibe C.M., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988, 1:403-406.
39. Stocchi F., Vacca L., De Pandis M.F., Barbato L., Valente M., Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol. Sci. 2001, 22:93-94.
40. Wenning G.K., Bösch S., Luginger E., Wagner M., Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv. Neurol. 1999, 80:545-548.
41. Fernandez H.H., Vanagunas A., Odin P., Espay A.J., Hauser R.A., Standaert D.G., et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Park. Relat. Disord. 2013, 19:339-345.
42. Antonini A., Albin R.L. Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology 2013, 80:784-785.
43. Wolz M., Hauschild J., Koy J., Fauser M., Klingelhofer L., Schackert G., et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Park. Relat. Disord. 2012, 18:994-997.
44. Reddy P., Martinez-Martin P., Antonini A., Calandrella D., Pilleri M., Odin P., et al. A multicentre European comparative survey of motor and non-motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in Parkinson's disease. Mov. Disord. 2012, 27:S49.
45. Martinez-Martin P., Reddy P., Antonini A., Henriksen T., Katzenschlager R., Odin P., et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J. Parkinsons Dis. 2011, 1:197-203.
46. Eggert K., Schrader C., Hahn M., Stamelou M., Russmann A., Dengler R., et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin. Neuropharmacol. 2008, 31:151-166.
47. Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 2009, 24:1468-1474.
48. Reddy P., Martinez-Martin P., Todorova A., Antonini A., Odin P., Martin A., et al. The EuroInf study: a multi-centre European comparative study of apomorphine versus intrajejunal levodopa infusion in a real life cohort of Parkinson's disease patients. 17th International Congress of Parkinson's Disease and Movement Disorders. Sydney, Australia 2013.
49. Antonini A., Yegin A., Preda C., Bergmann L., Poewe W. GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat. Disord. 2015, 21:231-235.
50. Kim H.J., Paek S.H., Kim J.Y., Lee J.Y., Lim Y.H., Kim M.R., et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J. Neurol. 2008, 255:1889-1894.
51. Loher T.J., Burgunder J.M., Weber S., Sommerhalder R., Krauss J.K. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2002, 73:395-399.
52. Arnulf I., Bejjani B.P., Garma L., Bonnet A.M., Houeto J.L., Damier P., et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000, 55:1732-1734.
53. Iranzo A., Valldeoriola F., Santamaria J., Tolosa E., Rumia J. Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry 2002, 72:661-664.
54. Monaca C., Ozsancak C., Jacquesson J.M., Poirot I., Blond S., Destee A., et al. Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. J. Neurol. 2004, 251:214-218.
55. Zibetti M., Torre E., Cinquepalmi A., Rosso M., Ducati A., Bergamasco B., et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur. Neurol. 2007, 58:218-223.
56. Reddy P., Martinez-Martin P., Rizos A., Martin A., Faye G.C., Forgacs I., et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin. Neuropharmacol. 2012, 35:205-207.
57. Lhommee E., Klinger H., Thobois S., Schmitt E., Ardouin C., Bichon A., et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012, 135:1463-1477.
58. Antonini A. Continuous dopaminergic stimulation - from theory to clinical practice. Parkinsonism Relat. Disord. 2007, (13(Suppl.)):S24-S28.
59. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2006, 355:896-908.
60. Weaver F.M., Follett K., Stern M., Hur K., Harris C., Marks W.J., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009, 301:63-73.
61. Schuepbach W.M., Rau J., Knudsen K., Volkmann J., Krack P., Timmermann L., et al. Neurostimulation for Parkinson's disease with early motor complications. N. Engl. J. Med. 2013, 368:610-622.
62. Williams A., Gill S., Varma T., Jenkinson C., Quinn N., Mitchell R., et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010, 9:581-591.
63. Di Rosa A.E., Epifanio A., Antonini A., Stocchi F., Martino G., Di Blasi L., et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol. Sci. 2003, 24:174-175.
64. Tyne H.L., Parsons J., Sinnott A., Fox S.H., Fletcher N.A., Steiger M.J. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J. Neurol. 2004, 251:1370-1374.
65. Drapier S., Gillioz A.S., Leray E., Peron J., Rouaud T., Marchand A., et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat. Disord. 2012, 18:40-44.
66. Epstein M., Johnson D., Hawes R., Schmulewitz N., Vanagunas A., Widnell K.L., et al. Gastrointestinal safety of the levodopa-carbidopa intestinal gel delivery system in treating advanced Parkinson's patients. Mov. Disord. 2013, 28:S144.
67. Reddy P., Martinez-Martin P., Brown R.G., Chaudhuri K.R., Lin J.P., Selway R., et al. Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a patient-reported outcome tool for advanced Parkinson's disease (PRO-APD). Health Qual. Life Outcomes 2014, 12:11.
68. Todorova A., Martinez-Martin P., Martin A., Rizos A.M., Reddy P., Chaudhuri K.R. Daytime apomorphine infusion combined with transdermal rotigotine patch therapy is tolerated at 2 years: a 24 hours treatment option in Parkinson's disease. Basal Ganglia 2013, 3:127-130.
69. Antonini A., Odin P., Opiano L., Tomantschger V., Pacchetti C., Pickut B., et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J. Neural Transm. 2013, 120:1553-1558.
70. Mancini F., Comi C., Oggioni G.D., Pacchetti C., Calandrella D., Coletti Moja M., et al. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat. Disord. 2014, 20:27-31.
71. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl. 3):S2-S41.
72. Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 2005, 20:523-539.